Incidence and predictors of organ failure among COVID-19 hospitalized adult patients in Eastern Ethiopia. Hospital-based retrospective cohort study

Abdi Birhanu¹*, Galana Mamo Ayana², Bedasa Taye Merga², Addisu Alemu², Belay Negash², Ahmed Seid³ and Yadeta Dessie²

Abstract

Background: Organ failure is incapability of at least one of the body organs to carry out a normal body functions. Identifying the predictors of the organ failure is crucial for improving COVID-19 patients' survival. However, the evidence related to this information is not well-established in developing countries, including Ethiopia. Therefore, this study aimed to determine the incidence and predictors of organ failure among adult patients admitted to Hiwot Fana Specialized University Hospital (HFSUH) COVID-19 treatment center from 1st May 2020 to 20th August 2021, Eastern Ethiopia.

Methods: A hospital-based retrospective cohort study design was implemented. Descriptive measures such as mean with standard deviation (SD), median with interquartile range (IQR), percentages, and frequencies were computed. The binary logistic regression was used to identify the association between outcome variables (organ functional status) and independent variables with an adjusted odds ratio (AOR) at a 95% confidence interval. A significance level was declared at a p-value of less than 0.05.

Results: The mean age of study participants was 47.69 years with the standard deviation (SD) of ±17.03. The study participants were followed for the median time of 8 days with IQR of 4, 14. The incidence of organ failure was 11.9 per 1000 person-day contribution (95% CI: 9.5, 14.9). Predictors such as age above 60 years (AOR = 1.71, 95% CI: 1.44, 4.53), smoking history (AOR = 5.07, 95% CI: 1.39, 8.15), cardiovascular disease (AOR = 5.00, 95% CI: (1.83, 11.72), and critical clinical stages of COVID-19 (AOR = 5.42, 95%: 1.47, 14. 84) were significantly associated with organ failure among COVID-19 hospitalized patients.

Conclusions: The incidence of organ failure was 11.9 per 1000 person-day contribution. Age, smoking, comorbidity, and clinical stages were significantly associated with organ failure among COVID-19 hospitalized cases. Therefore, clinicians should stringently follow the patients experiencing modifiable predictors of organ failure, especially patients with comorbidities and severe clinical stages. Moreover, the prevention programs that target elders and smokers should be strengthening to save this segment of populations before suffering from organ failure following COVID-19.

Keywords: COVID-19, SARS-CoV-2, Predictors, Organ failure, Comorbidity, Aged, Smoking, Ethiopia

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Background
The novel coronavirus disease-2019 was recognized in Wuhan China in December 2019 [1]. The causative virus SARS-CoV-2 has been spreading throughout the countries in the globe and was distinguished as a pandemic in March 2020 [2, 3]. A coronavirus commonly spreads from infected people to healthy individuals through infected air, making contact with fingers that contain the virus and then touching their eyes, nose, or mouth with unclean hands [2]. The pandemic, novel coronavirus disease 2019 (COVID-19) led to an unprecedented number of mortalities by causing damage of one or more organs of infected patients [4, 5].

The majority of COVID-19 cases (52%) developed respiratory disorders particularly, the acute respiratory distress syndrome [6]. Another complication such as heart failure, renal failure, liver damage, shock, and other organs failure triggered the early death of COVID-19 patients. The presence of comorbidities and clinical findings such as lymphocytopenia, elevated D-dimer, high fibrin degradation products, and disseminated intravascular coagulation (DIC) could lead to death. In addition, deep vein thrombosis (DVT), venous thromboembolism, pulmonary embolism (PE), systemic and pulmonary arterial thrombosis, embolism, ischemic stroke, and myocardial infarction (MI) are other commonly diagnosed clinical conditions that worsen the poor prognosis of COVID-19 patients [7, 8].

Moreover, another studies revealed that the COVID-19 clinical course could be complicated and end up with organ failure and death by factors such as gender, age (>60 years), comorbidities such as hypertension, diabetes, cardiovascular disease, acute respiratory distress syndrome (ARDS), could end up with organ dysfunctions and finally dead [9, 10]. Particularly, the risk factors associated with the development of ARDS may easily deteriorate the health of COVID-19-infected patients [11].

In order to prevent the organs failure, providing heated high flow oxygen, non-invasive ventilation, intubation, mechanical ventilation, vasopressors, and dialysis are common clinical managements being implemented in different clinical settings [12]. Therefore, distinguishing the burden of organ injuries due to COVID-19 is required for the betterment of clinical management of the patients. Additionally, understanding the predictors of organ failures is vital to identify high risky patients during pharmacological and non-pharmacological therapies provision. Despite that knowing the contributing factors of organ failure among COVID-19 patients could significantly contribute in the improvement of patient survival status, there is dearth of literatures in the resource-limited setups like Ethiopia. Therefore, this study aimed to assess the organ failure incidence and predictors amongst COVID-19 patients admitted to Hiwot Fana Specialized University Hospital.

Methods
Study setting and design
A hospital-based retrospective cohort study design was carried out in Harari Regional state in the Eastern part of Ethiopia. The regional state is situated on about 522 km away from the Capital city of Ethiopia (Addis Ababa) to the east. The region contains two public Hospitals that comprise Jugula General Hospital and Hiwot Fana Specialized University Hospital (HFSUH). This study was conducted in the HFSUH. In the Easter part of the country, the hospital serves as the largest teaching and referral center with about a total of 600 beds. The hospital manages the referral cases received from the Eastern part of Oromia Region, Somali region, Harari region, and Dire Dawa City administration. The hospital has been labeled as COVID-19 treatment center by Ethiopian Minister of Health (MoH) since the outbreak of COVID-19 in Ethiopia [13].

Participants and eligibility criteria
An adult patient admitted to Hiwot Fana Specialized University Hospital with the diagnosis of COVID-19 between May 2020 and August 2021 was included in this study. The patient whose information was incomplete for the variable of interests was excluded from the study (Additional file 1).

Sample size determination
The sample size was determined using proportion with the following formula:

\[ n = \frac{(z_{\alpha/2})^2 \times p \times q}{d^2} \]

where \( z_{\alpha/2} = 1.96 \) (95% CI), \( p = 70\% \), \( q = 30\% \), \( d = 0.05 \) (margin of error). \( n = 196 \times (0.7)(0.3)/0.05^2 = 323 \). Finally, by considering 10% of the possible proportion of withdrawals, the sample size was determined to be 355.

Operational definitions and variables in the study
An organ failure (Organ failed [yes/no]) among COVID-19 adult patients was a dependent variable of this study. The independent variables included sex, age, educational status, occupational status, marital status, residence, COVID-19 manifestations, clinical outcomes, utilization of mechanical ventilation, clinical management, laboratory findings, and comorbidities like Diabetic Mellitus (DM), hypertension, stroke, cardiovascular disorders, COPD, asthma, cancers, and HIV/AIDS were some of the commonly assessed diseases. Besides, alcohol consumption, medication history, and current smoking history were evaluated [15].
COVID-19 clinical stages are defined as follows; Asymptomatic infection; COVID-19 confirmed patients who test positive for SARS-CoV-2 using a virology test but who have no symptoms that are consistent with COVID-19. Mild illness; COVID-19 confirmed patients who have any of the various signs and symptoms of COVID-19 such as headache, vomiting, fever, sore throat, cough, muscle pain, nausea, diarrhea, malaise, and losing ability to taste and smell but who do not have shortness of breath, dyspnea, or abnormal chest imaging. Moderate illness; COVID-19 confirmed patients who show evidence of lower respiratory disease during clinical assessment or imaging and who have oxygen saturation (SpO2) greater than or equal to 94 percent on room air at sea level. Severe illness; COVID-19 confirmed patients who have SpO2 less than 94 percent on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen less than 300 mm Hg, respiratory count above 30 breaths/min, or lung infiltrates greater than 50 percent. Critical illness; COVID-19 confirmed patients who have respiratory failure, septic shock, and/or multiple organ dysfunctions. In this study, critical cases were defined as the cases that fulfilled the definition criteria of severe and critical illness, while non-critical patients were who fulfilled the definition criteria of both mild and moderate illness [16].

Organ failure is defined as incapability of at least one of the organ to carry out normal body functions. This failure includes at least one of lung failure, acute liver failure, acute kidney injury, cardiovascular disease, and wide spectrum of hematological abnormalities and neurological disorders as recognized by a physician [17].

SARS-COV-2 assaying procedures using RT-PCR

Laboratory examination materials such as Viral transport medium (VTM), swab sticks, ice-box, ice-pads, tongue depressor, marker, requisition form, and personal protective equipment (PPE) were prepared and used [18]. VTM used contains 3 ml fluids composed of gelatin and antimicrobial agents in a buffered salt solution. It was used to prevent the sample collected from drying, maintains the viability of the virus, and avoids the growth of contaminants. The swabs are made from rayon with plastic shaft. A Cotton or calcium alginate swab was avoided to be used since it may inhibit PCR reaction. Ice-box and ice-pads are used for maintaining a cold-chain during sample transportation from sample collection area to laboratory center. The ice-pad was filled with water and stored in the freezer (−20°C) before and after use [19–21].

Data collection method and produces

Five Bachelor of Science (BSc) holders nursing professionals were involved in the data collection. Also, two public health professionals were involved for supervising the data collection processes. Before the actual data collection, the data collectors took two days of training on the objective and relevance of the study. Regarding the SARS-CoV-2 sample testing, the standard procedure of SARS-COV-2 sampling and testing procedures were strictly followed and used. The sample contamination from the nasal vestibule was avoided by sterile opening of the outer case of the swab, inserting the swab into the mouth by slightly elevating the tip of the nose, and keeping the tip of the swab in the oropharynx for a few seconds, then rotated to achieve the highest absorption of oropharyngeal secretions [22, 23].

Statistical analysis

Data were entered into Epi-data version 3.1 and exported to STATA version 14.2 for analysis. Descriptive measures such as mean with standard deviation, median with inter-quartile range (IQR), percentages, and frequencies, and incidence density were performed. The binary logistic regression was used to identify the association between outcome variables (organ failed (Yes/No) and independent variables with an adjusted odds ratio (AOR) at a 95% confidence interval. Statistically, a significance level was declared at a p-value of less than 0.05.

Ethics approval and consent to participate

Research Ethical Review Committee (IHRERC) of Haramaya University College of Health and Medical Sciences ethically cleared this study. The study was conducted in accordance with the Declaration of Helsinki. Permission was obtained from Hiwot Fana Specialized University Hospital management. Due to the nature of retrospective study, it was difficult to reach the study participants to get informed consent directly from the patients. Instead, the written informed consent was obtained from the hospital head on behalf of the study participants to take information from the patients’ medical records anonymously guaranteeing the information confidentiality. All the data extraction procedures were conducted per the declaration of Helsinki.

Results

Socio-demographic and behavioral characteristics

A total of 355 hospitalized adult patients in the HFSUH COVID-19 treatment center between 1st May 2020 and August 2021 were included in this study. The mean age of the study participants was 47.69 years with the standard deviation (SD) of ±17.03. Nearly, three out of five patients (219/355, 61.69%) were males, while the rest were females. The majority of the study participants (303/355, 85.35%) were married. More than half (214/355, 53.6%) of the study subjects were employed.
More than one-third (143/355, 40.28%) of the patients had current smoking history. Nearly one-fourth of the study subjects (93/355, 26.20%) patients had an alcohol drinking history (Table 1).

Presence of comorbidities and clinical findings
The mean respiratory rate of the patients was 31.41 breaths per minute with the Standard deviation (SD) of ±10.29. The average heart rate of the study participants was 100.52 beats per minute (bpm) with the SD of ±20.31. The mean Serum creatinine (mmol/L) was 1.32 with SD of ±1.46. The mean lymphocyte count (1000/µL) was 18.05 with an SD of ±14.27. One hundred-seventy three patients had a history of taking chronic medication before being hospitalized with COVID-19. Regarding the COVID-19 symptoms, the majority of the patients presented with cough, fever, and shortness of breathing by 279/355 (78.59%), 258/355 (72.68%), and 243/355 (68.45%), respectively. Majorly the comorbidities were hypertension, Diabetic Mellitus, cardiovascular disease, and renal disease among 83/355(23.38%), 92/355(25.92%), 68/355 (19.15%), and 24/355 (6.76) patients, respectively. Eighty six (24.29%) of the study participants were in the critical COVID-19 clinical stage, while 54 (15.25%) were in severe COVID-19 conditions. During their hospital stay, 64 (18.03%) of the patients received dexamethasone medication. From the overall admitted patients, 96/355 (27.04%) of them died, while the rest 259/355 (72.96%) of them survived (Table 2).

Incidence and predictors of organ failure
The incidence of organ failure was 11.9 per 1000 person-day contribution (95% CI: 9.5, 14.9). The patients were followed for a minimum of 1 and a maximum of 74 days with a median follow-up time of 8 days [IQR, (4, 14)]. The proportion of patients with organ failure was 52/355, 14.6%. The organ failure included respiratory failure, renal failure, and cardiac failure. In the multivariable logistic regression model, age, smoking status, developing CVD, and COVID-19 critical clinical stage were statistically significant with organ failure (p < 0.05). Patients who were in the age group of above 60 years developed organ failure 1.71 times more likely than younger people (AOR = 1.71, 95% CI: 1.44, 4.53). COVID19 hospitalized patients who had a smoking history had a higher risk of developing organ failure 5.07 times more likely compared to non-smoker individuals (AOR = 5.07, 95% CI: 1.39, 8.15). Patients who presented with CVD had a risk of developing organ failure 5.00 times more likely than patients presented without comorbid cases (AOR = 5.00, 95% CI: (1.83–11.72). Patients who had critical clinical stages of COVID-19 cases had a risk of developing organ failure 5.4 times more likely compared to non-critical stages.(AOR = 5.42, 95%: 1.47, 14. 84) (Table 3).

Discussions
The study finding is lower than the findings from Shanghai (17%) [17, 24] and England (25%) [14] This discrepancy could be due to sociodemographic characteristics variation of the study population. In addition, the inclusion of an adequate sample in the present study may bring these differences as the former studies were conducted on a smaller sample size.

Patients who were in the age above 60 years developed organ failure 1.7 times more likely than younger people. Age is the most important non-modifiable sociodemographic characteristic that can affect the health status of an individual. As age increases, the kidney gradually drops its functions [25], maximum oxygen consumption declines, systolic pressure at rest increases [26], unfavorable respiratory mechanics related to reduced expiratory flows, high air trapping, and closing volume, and reduced gas interchange could.
be happened [27]. Studies showed that age has multiple effects on COVID-19 patients by aggravating the poor progression of the clinical outcomes that may result in organ failures and end up with death [28–31]. Therefore; these findings confirmed that elder individuals are at risk of developing severe COVID-19 clinical characteristics that can be manifested by organ failures.

COVID-19 hospitalized patients who had a smoking history had a higher risk of developing organ failure which was about 5 times more likely compared to non-smoker individuals. Smoking is a risk factor for several diseases and conditions, including heart and lung disease, cancer, and oral diseases such as periodontal [32]. On top of COVID-19 effects, smoking may exacerbate the severity of disease progression in causing organ failures complications [33, 34]. Moreover, Nicotine increases the vulnerability of the patients to COVID-19 and aggravates the disease progression through up-regulating the ACE2 expression [35]. Thus, the aggravations of clinical stages by smoking may cause organ failures.

Patients who presented with CVD had the risk of developing organ dysfunctions 5 times more likely than patients who presented without comorbid cases. It’s a fact that comorbidities have a strong association with the multi-organ damages among COVID-19 [36]. Particularly, the studies from China [37–41] showed that cardiac cases had a strong association with the COVID-19 clinical progression. This can be due to the organs which have been affected by comorbid cases before the onset of COVID-19 can be easily prone to damage.

Patients who had critical COVID-19 clinical stages had a risk of developing organ failure that was about 5.4 times more likely than those who had non-critical clinical stages. The advancement of COVID-19 clinical stages is probably triggered by the endothelial damage and thromboinflammation associated with the problem of the immune response [42, 43]. As clinical stages, progress to critical, cellular, and tissue level damages provoke the organs changes that induce multiple organ dysfunctions. The primary strength of this study could be the originality of this study for indicating the organ failure burden among COVID-19 hospitalized patients in resource-limited setting. This pioneer information for resource-limited setups might have clinical importance for the clinicians to closely following the patients with the organ failure predictors to prevent early death. The utilization of robust methods might make the study with stronger evidence than previously conducted studies. Moreover, the strength of this study could be its representativeness due to its adequate sample size enrollment compared to previous studies conducted in other countries. Even if the study has paramount strength, it could not be free from the limitation. This limitation could be that the expected organ failure among COVID-19 infected patients after discharge was not measured in this study. In addition, due to the nature of the retrospective study, the inclusion of all important variables could be difficult.

| Variables                          | Frequency (%) |
|------------------------------------|---------------|
| COVI-19 clinical stage             |               |
| Critical                           | 86 (24.29)    |
| Not critical                       | 268 (75.71)   |
| Medication history                 |               |
| Yes                                | 173 (48.73)   |
| No                                 | 182 (51.27)   |
| Cough                              |               |
| Yes                                | 279 (78.59)   |
| No                                 | 76 (21.41)    |
| Fever                              |               |
| Yes                                | 258 (72.68)   |
| No                                 | 97 (27.32)    |
| Shortness of breath                |               |
| Yes                                | 112 (31.55)   |
| No                                 | 243 (68.45)   |
| Hypertensive                       |               |
| Yes                                | 83 (23.38)    |
| No                                 | 272 (76.62)   |
| Diabetic                           |               |
| Yes                                | 92 (25.92)    |
| No                                 | 263 (74.08)   |
| Cardio vascular disease            |               |
| Yes                                | 68 (19.15)    |
| No                                 | 287 (80.85)   |
| Renal disease                      |               |
| Yes                                | 24 (6.76)     |
| No                                 | 331 (93.24)   |
| Receiving dexamethasone            |               |
| Yes                                | 64 (18.03)    |
| No                                 | 291 (81.97)   |
| Covid-19 outcome                   |               |
| Discharged                         | 259 (72.96)   |
| Death                              | 96 (27.04)    |
| Partial oxygen saturation(mmHg)   | 81.10 (SD ±16.63) |
| Respiratory rate (breath/minute)   | 31.41 (SD ±10.29) |
| Heart rate (bpm)                   | 100.52 (SD ±20.31) |
| Serum creatinine (mmol/L)          | 1.32 (SD ±1.46) |
| Lymphocyte count (1000/µL)         | 18.05 (SD ±14.27) |
Conclusions
The incidence of organ failure was 11.09 per 1000 person-day contribution. Age, smoking, comorbidity, and clinical stages were significantly associated with organ failure among COVID-19 hospitalized patients. The development of organ failure could be an early warning sign of poor clinical prognosis of COVID-19 patients. Therefore, clinicians should strictly follow the patients experiencing modifiable predictors of organ failure, particularly patients with comorbidities and severe clinical stages. Moreover, the COVID-19 prevention programs targeted to elders and smokers should be strengthening to save these groups of the population before suffering from organ failures following got ill from COVID-19.

Abbreviations
AOR: Adjusted Odds ratio; ACE2: Angiotensin converting enzyme 2; CVD: Cardiovascular Disease; IQR: Interquartile range; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2; COVID-19: Coronavirus Disease 2019; SD: Standard deviation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07402-6.

Additional file 1. Data collection tool.

Acknowledgements
We express our gratitude to Hiwot Fana Specialized University Hospital’s management and staff for their cooperation during data collection. Finally, we would like to appreciate the efforts of data collectors and supervisors for their priceless efforts they made to realize this research work.
Author contributions
AB was involved in conception and design of this study. GMA, BTM, AA, BN, AS, and YD participated in the analysis, finding interpretation, drafting and editing the manuscript. All authors read and approved the final manuscript.

Funding
This study was not funded.

Availability of data and materials
The dataset used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Research Ethical Review Committee (IHREC) of College of Health and Medical Sciences Haramaya University provided the ethical clearance. The study was conducted in accordance with the Declaration of Helsinki. Letter of permission was sent to Hiwot Fana Specialized University Hospital. Due to difficulty to reach patients to take informed consent, the consent was waived by the ethics committee. We obtained the informed consent from the head of the hospital to take information from the patients’ medical records anonymously guaranteeing information confidentiality.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of Medicine, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia. 2 School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia. 3 Hiwot Fana Specialized University Hospital, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Received: 4 September 2021 Accepted: 18 April 2022

Published online: 28 April 2022

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of 2019 coronavirus disease in Wuhan, China. Lancet. 2020;395(10223):497–506.
2. Patmuk S, Özkan A, Polat B. Epidemiology, pathogenesis, diagnosis and management of COVID-19. Tr-ENF. 2020;30:1–9.
3. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PloS Pathog. 2020;16(8): e1008762.
4. Kaushik P, Kaushik M, Parveen S, Tabassum S, Parvez S. Cross-talk between key players in patients with COVID-19 and ischemic stroke: a review on neurobiological insight of the pandemic. Mol Neurobiol. 2020;57(12):4921–8.
5. Tseng YH, Yang RC, Lu TS. Two hits to the renin-angiotensin system may play a key role in severe COVID-19. Kaohsiung J Med Sci. 2020;36(8):389–92.
6. Meen A, Ross-Degnan D, Wharam JF. Inaccurate estimates of negotiated reimbursement prices for insulin—reply. JAMA Intern Med. 2021;181(1):141–2.
7. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618.
8. Loganathan S, Kuppasamy M, Wankhar W, Gurugubelli KR, Mahadevappa VH, Lepcha L, et al. Angiotensin-converting enzyme 2 (ACE2): COVID-19 gate way to multiple organ failure syndromes. Respir Physiol Neurobiol. 2021;283:103548.
9. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the progression of COVID-19. J Med Virol. 2020;92(7):726–30.
10. Ayenigbara IO, Adeleke OR, Ayenigbara GO, Adegboro JS, Olofinyuyi OO. COVID-19 (SARS-CoV-2) pandemic: fears, facts and preventive measures. Germs. 2020;10(3):218.
11. Wu C, Chen X, Cari Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.
12. Alkhathami MG, Advani SM, Abalkhail AA, Alkhathami AM, Alshehri MK, Albeaesty EE, et al. Prevalence and mortality of lung comorbidities among patients with COVID-19: a systematic review and meta-analysis. Lung India. 2021;38(Suppl 1):S31.
13. Birhanu A, Ayana GM, Bayu M, Mohammed A, Dessie Y. Features associated with SARS-CoV-2 positivity among people presenting with acute respiratory tract infections to public Hospitals in Harari region, Ethiopia. SAGE Open Med. 2021. https://doi.org/10.1177/20503121211062793.
14. Iacobucci G. Long Covid: damage to multiple organs presents in young, low risk patients. BMJ. 2020;371:4470.
15. CDC February 12, 2021. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). https://search#. bvsalud.org/global-literature-on novel-coronavirus-2019 ncov/resource/ en/ppcovidwho-2607.
16. Clinical spectrum of SARS-CoV-2 infection. https://files.covid19treatment guidelines.nih.gov/guidelines/section/section_43.pdf
17. Mokhtari T, Hassani F, Ghafti N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J Mol Histol. 2020;51(6):613–28.
18. Ayana GM, Merga BT, Birhanu A, Alemu A, Negash B, Dessie Y. Predictors of mortality among hospitalized COVID-19 patients at a tertiary care hospital in Ethiopia. Infect Drug Resist. 2021;14:5363.
19. Abolnezhadian F, Makhvandi M, Alavi SM, Azaran A, Jallilian S, Rashno M, et al. Prevalence of SARS-CoV-2 in patients with severe pneumonia in Khuzestan Province. Iran Iran J Allergy Asthma Immunol. 2020;19(5):471–7.
20. Hueret-Pérez JA, Cabezas-Robelo C, Páez-Medina L, Hernández-Alvarez CA, Quant-Durán C, McKenrow JH. First report on prevalence of SARS-CoV-2 infection among health-care workers in Nicaragua. PLoS ONE. 2021;16(1):e0246884.
21. Dupraz J, Butty A, Dupreux O, Estoppey S, Falveir V, Thabard J, Zuppinger C, Greub G, Pantaleo G, Pasquier J, Rousson V. Prevalence of SARS-CoV-2 in household members and other close contacts of COVID-19 cases: a serologic study in canton of Vaud, Switzerland. InOpen forum infectious diseases 2021; Vol 8 No. 7, p. ofaf149. US, Oxford University Press
22. Torretta S, Zacchetti G, Cristofaro V, Ettori J, Solimeno L, Battilocchi L, et al. Diagnosis of SARS-CoV-2 by RT-PCR using different sample sources: a review of the literature. Ear Nose Throat J. 2021;110(2 suppl):S135-S138.
23. Torretta S, Zacchetti G, Cristofaro V, Ettori J, Solimeno L, Battilocchi L, et al. Nonserologic test for COVID-19: How to manage? Head Neck. 2020;42(7):1552–4.
24. Chen J, Qih T, Liiu, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai. China J Infect. 2020;80(5):e1–6.
25. Tiao JY, Semmens JB, Masarei JR, Lawrence-Brown MM. The effect of age on serum creatinine levels in an aging population: relevance to vascular surgery. Cardiovasc Surg (London, England). 2002;10(5):445–51.
26. Lakagga EG. Changes in cardiovascular function with aging. Eur Heart J. 1990;11:22–9.
27. Skloot GS. The effects of aging on lung structure and function. Clin Geriatr Med. 2017;33(4):447–57.
28. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in patients with COVID-19 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.
29. Yan H, Lu S, Chen L, Wang Y, Liu Q, Li D, et al. Multiple organ injury on admission predicts in-hospital mortality in patients with COVID-19. J Med Virol. 2020;92(7):726–30.
30. Romero Starke K, Peterheit-Haack G, Schubert M, Kampf D, Schliebner A, Hegewald J, et al. The age-related risk of severe outcomes due to COVID-19 infection: a rapid review, meta-analysis, and meta-regression. Int J Environ Res Public Health. 2020;17(16):5974.
31. Chai S, Li X, Lu X, Tan J, Abdelrahim MIA, Xu X. Effect of age of COVID-19 inpatient on the severity of the disease: a meta-analysis. Int J Clin Pract. 2021;75:e16460.
32. Weighing the risk of smoking during the COVID-19 pandemic: https://oralhealthsupport.ucsf.edu/news/weighing-risk-smoking-during-covid-19-pandemic.

33. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1045–56.

34. Gülsen A, Yigitbas BA, Uslu B, Dromann D, Kilinc O. The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis. Pulmonary medicine. 2020;2020:7590207.

35. Xie J, Zhong R, Wang W, Chen Q, Zou Y. COVID-19 and smoking: what evidence needs our attention? Front Physiol. 2021;12:603850.

36. Renu K, Prasanna PL, Valsala GA. Coronavirusopathies, comorbidities, and organ damage—a review. Life Sci. 2020;255:117839.

37. Robba C, Battaglini D, Pelosi P, Rocco PRM. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med. 2020;14(9):865–8.

38. Cárdenas Suri H, Jimomila BD. Catastrophic antiphospholipid antibody syndrome and multiple organ dysfunctions in critically ill patients with COVID-19. Expert Rev Respir Med. 2020;14(11):1071–2.

39. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA cardiology. 2020;5(7):811–8.

40. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.

41. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoibah H, Singh IP, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020;382(20):e60.

42. Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142(19):1881–4.

43. Yang L, Gou J, Gao J, Huang L, Zhu Z, Ji S, et al. Immune characteristics of severe and critical COVID-19 patients. Signal Transduct Target Ther. 2020;5(1):179.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.